Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,877 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose C Clear all
Terminated Phase 2 Interventional Results available

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

NCT00478140
View directory record Official record
Conditions
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Malignant Neoplasm, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
trastuzumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 19, 2026, 5:29 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4088044 in Healthy Participants

NCT07090785
View directory record Official record
Conditions
Healthy
Interventions
LY4088044, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Alamitos, California • Lenexa, Kansas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain

NCT03003715
View directory record Official record
Conditions
Trigeminal Neuropathic Pain
Interventions
PET Scans, transcranial direct current stimulation (tDCS), MRI, sham tDCS (prior to real tDCS)
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 19, 2026, 5:29 PM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
24
States / cities
Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

NCT01194037
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Genotype 1
Interventions
recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Los Angeles, California • National City, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)

NCT03759639
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
IB1001
Drug
Lead sponsor
IntraBio Inc
Industry
Eligibility
6 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

NCT06024239
View directory record Official record
Conditions
Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
Interventions
ABBV-932, Placebo for ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Los Alamitos, California • Grayslake, Illinois • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 50 Years
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
12
States / cities
Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 19, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

NCT07516951
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
CHF10067, Placebo
Drug · Other
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Dothan, Alabama • St. Petersburg, Florida • Hannibal, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00743795
View directory record Official record
Conditions
HCV Infection
Interventions
placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
48
States / cities
Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 19, 2026, 5:29 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

NCT04590781
View directory record Official record
Conditions
Merkel Cell Carcinoma, Small Cell Lung Cancer
Interventions
XmAb18087, XmAb18087 ± Pembrolizumab
Biological · Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Lebanon, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 19, 2026, 5:29 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Interventions
BMS-986504, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
44
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

NCT00326495
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Cetuximab, BAY 43-9006
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT01348919
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CEP-18770, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Augusta, Georgia • Lexington, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

NCT01190930
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
9,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
213
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 19, 2026, 5:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

NCT03276728
View directory record Official record
Conditions
Heart Failure, Healthy Volunteer
Interventions
AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 19, 2026, 5:29 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401
View directory record Official record
Conditions
Solid Tumors, CNS Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

NCT03196206
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 19, 2026, 5:29 PM EDT
Terminated Phase 3 Interventional

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

NCT06527404
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence

NCT01014533
View directory record Official record
Conditions
Alcohol Dependence, Insomnia
Interventions
Placebo dispensed to subject., Gabapentin dispensed to subject.
Drug
Lead sponsor
Dr. Kirk Brower
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

NCT01324180
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Metformin, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Intrathecal chemotherapy
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
1 Year to 30 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 19, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Decitabine and Talazoparib in Untreated AML and R/R AML

NCT02878785
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine, talazoparib
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 19, 2026, 5:29 PM EDT